Dermata Therapeutics Enhances Equity Plan and Approves Stock Split
Company Announcements

Dermata Therapeutics Enhances Equity Plan and Approves Stock Split

Dermata Therapeutics (DRMA) just unveiled an announcement.

Dermata Therapeutics, Inc. stockholders, in their 2024 Annual Meeting, have greenlit a significant amendment to their equity incentive plan which will increase the number of shares reserved for issuance and the annual addition of shares. Additionally, they approved a reverse stock split, appointed Moss Adams LLP as their independent accounting firm for the year, and passed a measure to adjourn the meeting if there weren’t enough votes for key proposals. The election of three directors to the board was confirmed with a majority vote.

For an in-depth examination of DRMA stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyDermata Therapeutics files to sell 5.87M shares of common stock for holders
TheFlyMorning Movers: Intel jumps after announcing AWS collaboration
TheFlyDermata Therapeutics announces $3.5M private placement priced at-the-market
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App